Európska únia - angličtina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile recombinant canarypox virus (vcp2017 virus) - immunologicals for equidae, horse, immunologicals - horses - active immunisation of horses from five months of age against west nile disease by reducing the number of viraemic horses. if clinical signs are present, their duration and severity are reduced.

Spojené štáty - angličtina - NLM (National Library of Medicine)

pharmaceutical associates, inc. - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - ibuprofen 100 mg in 5 ml - carefully consider the potential benefits and risks of ibuprofen oral suspension and other treatment options before deciding to use ibuprofen oral suspension. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). in pediatric patients, ibuprofen oral suspension is indicated: - for reduction of fever in patients aged 6 months up to 2 years of age. - for relief of mild to moderate pain in patients aged 6 months up to 2 years of age. - for relief of signs and symptoms of juvenile arthritis. in adults, ibuprofen oral suspension is indicated: - for treatment of primary dysmenorrhea. - for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see precautions – drug interactions ). ibupr

Spojené štáty - angličtina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 2 mg in 1 ml - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with: lorazepam is a schedule iv controlled substance. lorazepam is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse of benzodiazepines may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings: abuse, misuse, and addiction ). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). physical dependence lorazepam may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see warnings: dependence and withdrawal reactions ). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage (see dosage and administration: discontinuation or dosage reduction of lorazepam and warnings ). tolerance tolerance to lorazepam may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of lorazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Filipíny - angličtina - FDA (Food And Drug Administration)

n/a; importer: west wing pharma sales inc.; distributor: west wing pharma sales inc. - diclofenac (as sodium) - solution for injection (im/iv) - 25mg/ml (75mg/3ml)

Filipíny - angličtina - FDA (Food And Drug Administration)

n/a; importer: pharma-surrey international, inc.; distributor: west wing pharma sales inc. - multivitamins , dexpanthenol - solution for injection im/iv

Filipíny - angličtina - FDA (Food And Drug Administration)

n/a; importer: asianmeds, inc; distributor: west wing pharma sales inc. - ceftriaxone as sodium - powder for injection - 1 gram

Filipíny - angličtina - FDA (Food And Drug Administration)

eadriex pharmaceuticals phils., inc.; distributor: west wing pharma sales inc. - phenylephrine hydrochloride , brompheniramine maleate - syrup (oral drops) - 6.25 mg/2 mg per ml

Filipíny - angličtina - FDA (Food And Drug Administration)

eadriex pharmaceutical phils., inc.; distributor: west wing pharma sales inc. - ciphonex - syrup - 12.5 mg/4 mg per 5 ml

Filipíny - angličtina - FDA (Food And Drug Administration)

euro-health care exponents, inc.; distributor: west wing pharma sales inc. - fusidic acid - cream - 0.02

Filipíny - angličtina - FDA (Food And Drug Administration)

euro-healthcare exponents, inc.; distributor: west wing pharma sales, inc. - mupirocin - ointment - 20 mg/g (2% w/w)